Xiong’s research indicates that the advantages of GLP-1RA in PCOS may derive from systemic metabolic reconfiguration driven by microbial metabolites, especially short-chain fatty acids that influence insulin sensitivity and inflammatory response, alongside direct ovarian impacts [34]. This evidence concerns the gene INS and polycystic ovary syndrome.